Immunic, inc. reports top-line data from phase 2 caldose-1 trial of vidofludimus calcium in patients with moderate-to-severe ulcerative colitis and provides corporate update

– trial did not achieve primary endpoint in the ulcerative colitis (uc) population caused by unexpected interference between vidofludimus calcium and concurrent use of corticosteroids – – in uc population without concurrent steroid use, pooled vidofludimus calcium data suggest activity in clinical remission over placebo; counterbalanced by interference observed in the uc population with concurrent steroid use – – company does not plan further development activities in ulcerative colitis without a partner – – focus to remain on ongoing phase 3 development of vidofludimus calcium in multiple sclerosis, and ongoing imu-935 and imu-856 programs with clinical data for both expected in 2022 – – $93.1 million in cash and cash equivalents as of may 31, 2022 expected to fund immunic into the fourth quarter of 2023 – – conference call and webcast, including a corporate update, to be held today, june 2, 2022 at 8:00 am et – new york , june 2, 2022 /prnewswire/ -- immunic, inc. (nasdaq: imux), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused on treating chronic inflammatory and autoimmune diseases, today reported top-line data from its phase 2 caldose-1 trial of lead asset, vidofludimus calcium (imu-838), the company's selective oral dhodh inhibitor, in patients with moderate-to-severe ulcerative colitis (uc) (clinicaltrials.gov: nct03341962). the trial did not achieve the primary endpoint of clinical remission for the pooled 30 and 45 mg/day active dose groups of vidofludimus calcium versus placebo at week 10.
IMUX Ratings Summary
IMUX Quant Ranking